CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 115 filers reported holding CYMABAY THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $489,048 | -15.4% | 32,800 | -37.9% | 0.02% | -17.2% |
| Q2 2023 | $578,160 | +25.6% | 52,800 | 0.0% | 0.03% | +16.0% |
| Q1 2023 | $460,416 | +39.1% | 52,800 | 0.0% | 0.02% | +25.0% |
| Q4 2022 | $331,056 | +78.9% | 52,800 | 0.0% | 0.02% | +66.7% |
| Q3 2022 | $185,000 | +18.6% | 52,800 | 0.0% | 0.01% | +20.0% |
| Q2 2022 | $156,000 | -4.9% | 52,800 | 0.0% | 0.01% | +25.0% |
| Q1 2022 | $164,000 | -28.7% | 52,800 | 0.0% | 0.01% | -38.5% |
| Q2 2021 | $230,000 | -3.8% | 52,800 | 0.0% | 0.01% | -13.3% |
| Q1 2021 | $239,000 | -21.1% | 52,800 | 0.0% | 0.02% | -28.6% |
| Q4 2020 | $303,000 | -33.0% | 52,800 | -15.5% | 0.02% | -40.0% |
| Q3 2020 | $452,000 | +172.3% | 62,500 | +31.6% | 0.04% | +150.0% |
| Q2 2020 | $166,000 | – | 47,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |